Prime Medicine Announces Goldman Sachs Healthcare Conference Presentation June 10 — PM577 Wilson Disease IND on Track for H1 2026 Filing; PM647 AATD IND Mid-2026

Prime Medicine (PRME) announced on June 3, 2026 that CEO Allan Reine, M.D., will present at Goldman Sachs' 47th Annual Global Healthcare Conference in Miami Beach, Florida on June 10, 2026 at 10:40 a.m. ET, providing an update on the company's prime editing pipeline. Key milestones: (1) PM577 (Wilson disease, prime editing) — regulatory application (IND and/or CTA) targeted for H1 2026, i.e., by June 30, 2026. PM577 corrects the H1069Q variant — the most common mutation in Wilson disease — using prime editing without double-strand DNA breaks, achieving >80% mutation correction and full restoration of copper homeostasis in mouse models at week 8 post-administration with no detected off-target editing. Initial clinical data are expected in 2027. (2) PM647 (alpha-1 antitrypsin deficiency, AATD, prime editing) — IND/CTA submission targeted for mid-2026, with clinical data expected in 2027. (3) PM359 (chronic granulomatous disease, CGD) — ongoing FDA regulatory dialogue toward a BLA for accelerated approval; PM359 prime editing data in two patients were published in NEJM in December 2025, and the company is currently in formal pre-BLA discussions with the FDA. Wilson disease prime editing data were also presented at the ASGCT Annual Meeting (May 11–15, Boston) and subsequently at the Jefferies Global Healthcare Conference on June 4, 2026. Prime Medicine held $149.2M cash with runway into 2027.